Ruchi Patel

Graduated but still working on my thesis project… • NCSU ‘17 • JHU ‘19 • UPenn ‘24

[Nicholas Aboreden @ngaboreden]

Excited to share that my second paper from graduate school is out now at Nature Genetics. We show that Enhancer-Promoter interactions can form de novo in the absence of loop extrusion.

https://t.co/GOGyzCf8U8

[Patrizia Porazzi @PatriziaPorazzi]

Exciting news: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models @Cancer_Cell @MarcoRuella @AlbertoCarturan @PuneethGuru_ @_ruchipatel @yunlin_zhang_ @guido_ghilardi and my stellar co-author Siena Nason

https://t.co/evGp8LmsMN

[Nicholas Aboreden @ngaboreden]

Excited to share our latest work on bioRxiv! Using cell-cycle dynamics and NIPBL depletion, we show that long-range enhancer interactions can form de novo without loop extrusion. Alternative mechanisms, including LDB1 and YY1, may play key roles.https://t.co/CgBN4QJcuL

[Nicholas Aboreden @ngaboreden]

https://t.co/dwugzdQRsT

Our paper is now online @MolecularCell. Architectural protein LDB1 drives enhancer connectivity independently of CTCF/cohesin!

[Puneeth Guruprasad @PuneethGuru_]

Wild experience to have seen our story shared at the #ASH24 Plenary in San Diego by my wonderful co-lead @Shan_Liu_ ! Looking forward to further proving that we can enhance cancer treatment by modulating readily-actionable patient lifestyle factors.

[Alberto Carturan @AlbertoCarturan]

Grateful to #ASH2024 for the chance to present our work on overcoming the absence of CD2:CD58 co-stimulation using an innovative PD1:iCD2 switch receptor. Thanks to my mentor @MarcoRuella and the @RuellaLab for their invaluable support. Excited to delve deeper into this approach!

[Penn Medicine @PennMedicine]

Learn more about the exciting advances in blood cancer and benign hematology research that Penn Medicine and @PennCancer experts will be presenting at the @ASH_hematology Annual Meeting this weekend. #ASH24 https://t.co/U3XQpA89Ae

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

#ASH24 Energy matters! Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate #CARTCell #TCell #tcellrx #immunotherapy @PennMedicine
https://t.co/siNMMchAuO

[Penn Medicine @PennMedicine]

A simple dietary supplement may provide a new approach to boost #CART cell function – hear more in the #ASH24 Plenary Session today. @MarcoRuella @MaayanLevy_Lab @PuneethGuru_ https://t.co/8SnrY5iJGd

[Ruchi Patel @_ruchipatel]

Looking forward to discussing our latest work on CD5 next week! Register here to join: https://t.co/um7QA6PQ5k

[Kartik Patel, MD, MBA @KartikPatelMD]

Very excited to share this work that could not have been done without the help of @RaisBahrami and @arnabguonc ! Big thank you to The Oncologist for this opportunity!

[Nicholas Aboreden @ngaboreden]

Happy to share my thesis work, now online at bioRxiv. We show that LDB1 organizes Enhancer-Promoter interaction networks and can function independently of cohesin!

https://t.co/rSSZPpv4Bh

[Penn Medicine Cancer @PennCancer]

The effectiveness of #CARTCellTherapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, according to research led by @PennCancer's Dr. @MarcoRuella. https://t.co/UPgMLh7dx2

[Penn Medicine CSO @PennMedCSO]

In a study published in @SciImmunology, @PennMedicine researchers identify #CD5 as an immune checkpoint protein & potential target of future cancer therapies ft. @MarcoRuella (@PennCancer) https://t.co/8nC1QIWCuH

[Parker Institute for Cancer Immunotherapy @parkerici]

@UCLA @UCSF @cityofhope @DanaFarber A discovery from PICI Investigators @Penn has revealed that deleting the CD5 gene in CAR T cells significantly enhances their antitumor activity across multiple cancer types, opening new avenues for more potent and effective immunotherapies. https://t.co/S4VfmPDXaw (5/5)

[ACIR @ACIR_org]

Patel et al. used the CRISPR-Cas9 system to ablate expression of the TCR-associated T cell inhibitory receptor CD5 from CAR T cells of several specificities and TCR-redirected T cells. https://t.co/Og6DA7IOnz  @_ruchipatel  @MarcoRuella @PennMedicine

[Ruchi Patel @_ruchipatel]

Looking forward to joining @pillar_vc Frequency Bio's Cohort 10 next week! Excited to learn more about the biotech startup community.

[Science Immunology @SciImmunology]

Genetic deletion of #CD5 in CAR T cells given to mice led to enhanced expansion, persistence, and anti-tumor effects against a range of preclinical solid and blood #cancer models.

Read more in Science #Immunology: https://t.co/krHkOKS1sk

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

NEW -CD5 deletion enhances the antitumor activity of adoptive T cell therapies in vivo (liquid & solid cancer models) by enhancement of T signaling, cytotoxicity, and persistence. Stellar work by @_ruchipatel @MarcoRuella @PennMedicine @SciImmunology https://t.co/jqrgPgcgc6

[Penn Medicine @PennMedicine]

A @PennCancer research team led by @MarcoRuella has found that CD5 knockout boosts #CARTcell anti-tumor efficacy, in a preclinical study published in @SciImmunology. https://t.co/7OsiP2tDWZ